Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: William Fraser Symmans, Christina Yau, Yunn-Yi Chen, Brian Datnow, Shi Wei, Michael D Feldman, Jon Ritter, Xiuzhen Duan, Beiyun Chen, Ronald Tickman, Husain Sattar, Anthony Martin Magliocco, Bhaskar Kallakury, Megan Troxell, Smita Asare, Minetta C. Liu, Angela DeMichele, Douglas Yee, Donald A. Berry, Laura Esserman, I-SPY 2 TRIAL Investigators and Pathologists
Institutions: The University of Texas MD Anderson Cancer Center, Buck Institute for Research on Aging, University of California, San Francisco, University of California San Diego, University of Alabama at Birmingham, University of Pennsylvania, University of Minnesota, Loyola University Medical Center, Loyola Medicine, Mayo Clinic, University of Washington, University of Chicago Medical Center, Moffitt Cancer Center, Georgetown University, Oregon Health & Science University, Quantum Leap Healthcare Collaborative, Abramson Cancer Center, Masonic Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2805728329